Partner with the Leaders Building Medtech

Enrique Vega

CEO

Azalea Vision is developing a solution for patients with conditions and disorders that increase sensitivity to light. The company's solution actively adapts and manages within a personalized contact lens. The lens will also be capable of compensating for refractive errors of the eye, such as astigmatism and myopia. Visit website.

Amit Vohra

Founder, President & CEO

Next generation office-based modular MRI and MRI based technologies. Initial focus on advancing the solutions for prostate disease management and other urology and pelvic conditions. Visit website.

Ilan Uchitel

CEO

CAPS Medical is developing a solution to treat a wide range of solid tumors using Non-thermal Atmospheric Plasma (NTAP). This minimally invasive procedure selectively destroys cancer cells without damaging the surrounding healthy tissue.  Visit website.

Hamed Hanafi

President & CEO

NovaResp is developing technology to improve the prediction of respiratory events in patients using positive airway pressure (PAP) machines. The company's platform uses artificial intelligence and machine learning to monitor respiration and prevent detrimental episodes of apnea.  Visit website.

Laurent Laferriere

Co-Founder & CEO

Ditch Labs is an early-stage startup developing a digital platform for the treatment of substance abuse disorders. The platform uses software/device combination to address the physiological and psychological addiction concurrently. The platform is initially being developed for the treatment of smoking cessation/nicotine addiction using the DitchPen medical vaporizer that pairs with a digital therapeutic that learns, adapts, and assists patients through the withdrawal process. Visit website.

Georgi Kadrev

Co-Founder & CEO

Kelvin Health uses a mobile thermal imaging camera to capture the head of the body and then analyzes those images with AI to detect anomalies related to vascular conditions. The company's technology offers new insights intended to improve the management of patients with vascular diseases.  Visit website.

Stuart Mitchell

Founder/CEO

Novuson’s patented DTU technology will represent the first substantive innovation in over 25 years for targeting vessel sealing / dividing, and hemostasis (bleeding control) in surgical and trauma applications. Visit website.

Mike Karim

CEO

Having been spun-out from Oxford University, Oxford Endovascular is developing OxiFlow, a next-generation flow-diverter to reduce the risk of complications and ruptures in patients with intracranial aneurysms. Visit website.

James Lancaster

CEO

Solenic Medical is developing a non-invasive medical device that utilizes alternating magnetic fields to eradicate biofilms that form on implants. The company's platform uses external magnetic coils to destroy infective biofilms on the surface of knee and hi replacement implants, as well as plates and rods for trauma related procedures. Solenic's solution is being developed to replace the expensive and risky two-step revision surgery, which is the current standard of care for chronic infections on medical implants. Visit website.

Ofer Sharon

CEO

OncoHost aims to help providers and patients understand a patient's unique response to cancer therapies. The PROphet platform combines bioinformatics, system biology, proteomic pattern recognition, and machine learning to provide clinicians with actional clinical insights to optimize patient therapy.  Visit website.

Pablo Fernandez Echeverria

CEO

Polimerbio is focused on the research, development, and manufacture of biodegradable medical devices based on the company's extensive knowledge and experience in polymer chemistry. Within the company's portfolio of products in development are a biodegradable stent for the treatment of urethral stricture and scaffolds for the regeneration of spinal cord injuries. Visit website.

Giorgio Castagneto Gissey

CEO

Keyron Medical is an early-stage medtech company focused on treating Type 2 diabetes, NASH, and obesity, in addition to other metabolic diseases. The company's ForePass device features an innovative design that enables a non-invasive bypass at the duodenal level. The device is inserted via endoscopy without requiring a single incision, thereby allowing the device to avoid the risks of traditional gastric bypass surgery. In animal models, the device has been shown to completely reverse Type 2 diabetes. Visit website.

Jordan Pollack

CEO

VeinWay is addressing the challenges in treating venous chronic total occlusions. Crossing veins is currently a time-consuming endeavor that remains challenging enough for failures to occur. The company's Traversa catheter has been designed to penetrate blockages with its unique features, including: a steerable needle to maintain navigational control, a 6mm balloon that anchors the device to enhance needle penetration, and a braided catheter that balances catheter strength and flexibility. Visit website.

David Danielsen

CEO

CairnSurgical is developing an innovative tool to guide surgical interventions in patients with cancer. The company's Breast Cancer Locator (BCL) is a proprietary, patient-specific, 3D printed surgical guide intended to reduce positive margins during breast cancer tumor removal. The solution uses MRI data to create a personalized model that assist surgeons in localization and excision of tumors to reduce positive margins. Visit website.

Jochen Hampe

CEO

ConnCons integrates connectivity into infusion consumables to create a cloud to vessel end-to-end digital solution. The system enables safer, faster and automated therapies with a superior patient experience. First clinical applications are targeted at both center-based and home oncological therapy. Visit website.

Ludovic Le Meunier

CEO

THERYQ specializes in the design and production of linear accelerators for radiotherapy. The company's FLASH technology is intended to increase the effectiveness of radiotherapy, by taking the conventional radiotherapy process requiring multiple treatment sessions and weeks of irradiation and condensing it into a single procedure performed in milliseconds. The result of this high energy radiotherapy is a reduction in the side effects while simultaneously increasing treatment efficacy. Visit website.

Toon Overbeeke

Co-Founder & CEO

Vitestro is developing an autonomous platform for drawing blood. The company's device combines AI-based, ultrasound-guided 3D reconstruction with robotic needle insertion to insure accurate and secure blood collection.  Visit website.

Filip Peters

CEO

Acorai is developing a non-invasive monitoring solution to measure pulmonary artery pressure. The handheld device utilizes a unique combination of acoustic, electrocardiographic, pressure, seismic and visual sensors to collect robust data to be analyzed using a machine learning engine to evaluate heart failure progression. The company's solution is an alternative to the current standard procedure, which involves right heart catheterization performed in a catheterization lab to evaluate heart functionality. Visit website.

Lloyd Mencinger

President & CEO

Treating type 2 diabetes and GI disease with 30 minute, out-patient, endoscopic ablation therapy Visit website.

Andrew Cameron

CEO

FeelTect's Tight Alright is a connect-health platform that provides data-driven, targeted, and consistent compression therapy for the treatment of venous leg ulcers. The solution employs a point-of-care wearable pressure sensing device that optimizes traditional compression therapy to reduce healing time, frequencies in healthcare visits, and costs to treat. Visit website.

John Zak

President and CEO

TecTraum has designed and developed a novel medical device for the treatment of concussions. The company's pro2Cool device is a non-invasive, portable system that delivers hypothermic therapy to the head and neck to reduce the impact and symptoms of traumatic brain injuries. TecTraum has received Breakthrough Device Designation from the U.S. FDA for pro2cool. The company has submitted a de novo filing for consideration for market authorization with the FDA that is currently under review. Visit website.

Berk Tas

CEO

Transforming the experience for both patient and clinician in interventional procedures with a 3D augmented reality platform featuring real-time holographic visualization of the patient’s actual anatomy, “floating” over the patient. Visit website.

Rob Hill

CEO

TAE Life Sciences, a subsidiary of TAE Technologies, is leveraging accelerator-based neutron beam technology for Boron Neutron Capture Therapy (BNCT) to bring promising treatment potential for head and neck, glioblastoma multiforme (GBM) and other cancers that are difficult to treat with traditional methods.  Visit website.

Almog Aley-Raz

CEO

CorNeat Vision has developed a proprietary platform for developing nondegradable, biomimetic biomaterials to treat diseases. The company's EverMAtrix material is a 100% synthetic, nondegradable porous material that mimics the micro-structure of the extracellular matric (ECM). CorNeat's technology has been applied to products for dental and ophthalmic surgery.  Visit website.

Caitlin Morse

CEO

BrainSpace is developing a solution to simplify critical care in neurocritical patients. BrainSpace is committed to improving the way brain pressure is managed in patients recovering from stroke, traumatic brain injury, and neurosurgery. Currently patients requiring intracranial pressure management must be meticulously monitored and measured hourly by a nurse. The company has developed an automated monitoring solution as an alternative to the antiquated drainage monitoring relying on a manometer-based drain and blood pressure monitor that eliminates the hassle for patients and providers while improving the quality of data being captured for researchers and physicians. Visit website.

Evan Luxon

CEO

Transforming surgical drainage with intelligent digital devices to reduce complications and costs in patients recovering from cardiothoracic surgery. Visit website.

Jordi Martorell

CEO & Co-Founder

Aortyx is developing a solution for the treatment of aortic dissection. The company is developing a biomimetic, bioresorbable endovascular patch that is deployed via an endovascular catheter. The patch is designed to cover an aortic tear, stop false lumen blood flow, and promote natural repair and bio-integration at the tear site.  Visit website.

Bryan Lord

CEO

Pristine Surgical makes a high definition single-use visualization system for minimally invasive surgery and delivers its visualization devices in complete single-use kits. The devices utilize a low-cost image processing unit which also serves as a portal to cloud-based software supporting the entire surgical episode. Visit website.

Rob Krummen

CEO

Vektor Medical's vMAP system helps identify the sources of stable and unstable arrhythmia using accessible, noninvasive electrocardiogram (ECG) data. Clinicians upload ECG data into the vMAP system, which then interprets and visualizes the data in 3D to identify sources of arrhythmia inside and outside of the heart. The FDA-cleared  vMAP system is capable of creating a "heat map" of the heart in < 3 minutes to support or improve ablation treatment planning. Visit website.

Stephen Cox

CEO

InVera Medical is developing a catheter-based therapy for chronic venous disease.  The device uses non-thermal energy to disrupts the inner vessel lining, resulting in natural scarring and vessel closure that diverts blood flow away from diseased vessels. Visit website.

Pierre Lemire

CEO

Kent Imaging is using multispectral oxygenation imaging to enhance the care of chronic wounds. The company's lead product, SnapshotNIR, is a portable tool that utilizes near-infrared (NIR), reflectance-based technology to measure tissue oxygen saturation in superficial tissue. The information collected by the device improves the data available to care providers when making medical decisions that positively impact patient outcomes in wound care. Visit website.

Pedro Costa

CEO

Interventional Systems develops B2B and OEM surgical robotic platform solutions for minimally invasive surgery and percutaneous interventions. The company partners with other medical device manufacturers to offer them a customizable CE-Marked, FDA Cleared robotic platform that the partners can commercialize in combination with their therapeutic products (such as implants, needles, guidewires, etc.). Interventional Systems establishes and maintains the whole enabling processes and operations related to a robotics program, allowing the partner to focus on the commercialization efforts. Visit website.

Sebastien Ladet

CEO

Affluent Medical is a next-generation prostheses developer building a portfolio of therapies for the treatment of cardiovascular and urological diseases. The company's cardiovascular products consist of the Kalios annuloplasty device that can be adjusted percutaneously and the Epygon, a bio-prosthesis for transapical mitral valve replacement. To address stress urinary incontinence, the company is developing Artus, a remote-controlled implant that returns control of voiding to patients suffering from this condition. Visit website.

Yosef Safi Harb

Founder and CEO

Happitech has developed a CE-marked, smartphone-based method for effective remote monitoring of patients. The company's core competencies in artificial intelligence (AI) integration and photoplethysmography (PPG) enable effective and accurate measurement of heart rate and atrial fibrillation. Visit website.

Leo Smit

CEO

Hy2Care's vision is to support patients in the fight against osteoarthritis. The company's lead product, CartRevive, is a hydrogel implant composed of dextran and hyaluronic acid conjugates that form a resorbable scaffold when injected. The hydrogel enables natural restoration of tissue defects by creating an environment conducive to cell regrowth that proceeds towards the restoration of smooth hyaline cartilage.  Visit website.

Michael Ebner

CEO & Co-Founder

Hypervision Surgical is developing an AI-driven intraoperative imaging system for wide-field tissue differentiation to identify normal tissue, nerves, blood vessels and tumors in real time. The technology is non-invasive, non-contact and does not require the use of exogenous contrast agent.  Visit website.

Anita Brinks

COO

ATRO Medical's Artimis prosthesis is intended to provide patients who are too young for a knee replacement yet suffering from chronic knee pain with a viable solution. Artimis is a flexible, artificial meniscus that offers patients a less invasive alternative for treating chronic knee pain. Visit website.

David Neale

CEO

Arga Medtech is developing a next-generation solution for the treatment of cardiac arrhythmia and atrial fibrillation. The company's Coherent Sine-burst Electroporation (CSE) uses a proprietary puled-field ablation (PFA) generator and catheter to offer a single-shot device capable of producing linear and focal lesions safer, more efficiently and faster than existing technologies used to treat cardiac arrhythmias today. Visit website.

Laurence Marsteller

CEO

Next-generation beta ophthalmic applicator. Visit website.

Ruben Molina

CEO and Co-Founder

INNITIUS is a medical device startup that develops a new technology (Torsional Waves) for the numerical and objective quantification of cervical consistency. This technology is reproducible between different users and, in combination with diagnostic algorithms that include this variable together with other clinical history variables, will be used for the diagnosis of any pathology related to changes in the consistency of cervical tissue in women in the different stages of life globally. The first pathology targeted by the company is the diagnosis of Threatened Preterm Labor. Visit website.

Oriol Iborra

CEO & Co-Founder

Every year, 4M new coronary stents are implanted to maintain the arteries’ functionality of patients who suffered a heart attack. However, 30% of these stents will fail within two years, and the sole method available to cardiologists to monitor stent malfunction is an angiogram—an invasive and ionizing procedure performed during surgery. We introduce the NIMBLE System, a first-in-class, non-invasive, non-ionizing microwave-based technology that enables cardiologists to obtain objective data about the status of coronary stents. This includes level of occlusion, potential fractures, or migrations that could endanger patients' lives. NIMBLE addresses a massive blue ocean market of $8 billion, allowing cardiologists to take control of their patients with heart failure, providing objective data through a convenient, non-invasive technology, aiming to save millions of lives. Visit website.

Jochen Reinöhl

CEO

Coramaze Technologies is developing an fast end effective solution for the treatment of tricuspid regurgitation. The TriPair system is deigned to be anchored atraumatically to the right atrium. The device is intended to be easily placed in a procedure taking less than twenty minutes, without the need for anesthesia or TEE. TriPair is agnostic of valve morphology and can be retrieved if necessary Visit website.

Mario Arico

CEO & Co-Founder

Twinical is developing a novel solution for soft-tissue surgical planning and navigation. The company's technology combines artificial intelligence and augmented reality to provide surgeons with digitally-enhanced visual guidance during surgery. Visit website.

Barry Allen

President & CEO

Sonic Incytes' Velacur is a portable, handheld ultrasound that integrates machine learning to enhance image guidance, resulting in a confident assessment of liver health in all body types. Scans using the Velacur system can be performed in the physician office in approximately 5 minutes, producing real-time measurements of liver stiffness and attenuation.  Visit website.

Adriann Hart de Ruijter

Chairman

Preventicus provides managed care programs and technology for cardiovascular disease through early detection, diagnosis and monitoring. Innovative telecare technology, clinical evidence and proven health-economic outcomes, in compliance with medical guidelines, offer value to patients and health insurances Visit website.

Dominic Senn

CEO

MachineMD’s focus is the creation of automated, quantifiable, and standardized medical examinations to improve the quality and efficiency of healthcare. The company’s mission is to bring the diagnostic quality of trained tertiary care specialists into secondary and primary care sites for the diagnosis and monitoring of neurological disorders. At the core of the company’s approach is the evaluation of biomarkers related to eye movements and pupillary function using artificial intelligence and virtual reality.  Visit website.

Pau Rodriguez

CEO

Methinks vision is to provide universal and timely medical assistance to enable life-saving treatments worldwide. The company is initially focused on stroke, the second most common cause of death and a major cause of disability globally. Its AI software, Methinks Stroke Suite, is capable of assisting in stroke triage and providing decision support for life-saving treatment using the simplest medical imaging (non-contrast CT), with the potential to optimize stroke triage and reduce time to treatment. Visit website.

Bracy Fertig

Founder, CFO

For industry partners bringing innovative solutions to market: Caresyntax offers clinical data services, data science expertise, and AI-enabled tech modules to collect meaningful data straight from the point of care. The company's services capture value for the end-user and produce actionable insights to drive commercial growth and product development needs. Visit website.